Relationship between tumour size and outcome in pancreatic ductal adenocarcinoma. BJS 2017; 104: 600-607.
Published: 8th February 2017
Authors: D. Ansari, M. Bauden, S. Bergström, R. Rylance, G. Marko‐Varga, R. Andersson et al.
The size of pancreatic ductal adenocarcinoma (
Patients diagnosed with
Some 58 728 patients were included. There were 187 patients (0·3 per cent) with a tumour size of 0·5 cm or less, in whom the rate of distant metastasis was 30·6 per cent. The probability of tumour dissemination was associated with tumour size at the time of diagnosis. The association between survival and tumour size was linear for patients with localized tumours, but stochastic in patients with regional and distant stages. In patients with resected tumours, increasing tumour size was associated with worse tumour‐specific survival, whereas size was not associated with survival in patients with unresected tumours. In the adjusted Cox regression analysis, the death rate increased by 4·1 per cent for each additional 1‐cm increase in tumour size.
Pancreatic cancer has a high metastatic capacity even in small tumours. The prognostic impact of tumour size is restricted to patients with localized disease.Read more
You may also be interested in
Authors: R. Green, S. C. Charman, T. Palser
Notes: Variation in compliance related to outcomes
Authors: T. Maeta, T. Ebata, E. Hayashi, T. Kawahara, S. Mizuno, N. Matsumoto et al.
Notes: Poor survival despite portal vein resection
Average treatment effect of hepatic resection versus locoregional therapies for hepatocellular carcinoma.
Authors: A. Cucchetti, V. Mazzaferro, A. D. Pinna, C. Sposito, R. Golfieri, C. Serra et al.
Notes: Resection is better
Meta‐analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma.
Authors: S. Erridge, P. H. Pucher, S. R. Markar, G. Malietzis, T. Athanasiou, A. Darzi et al.
Notes: No evidence for best treatment
Meta‐analysis of single‐port versus conventional laparoscopic cholecystectomy comparing body image and cosmesis. BJS 2017; 104: 1141-1159.
Authors: R. Haueter, T. Schütz, D. A. Raptis, P.‐A. Clavien, M. Zuber
Notes: Single port superior for cosmesis, body image and pain
Systematic review of the influence of chemotherapy‐associated liver injury on outcome after partial hepatectomy for colorectal liver metastases.
Authors: J. Zhao, K. M. C. van Mierlo, J. Gómez‐Ramírez, H. Kim, C. H. C. Pilgrim, P. Pessaux et al.
Notes: Increased complications in severe SD and steatohepatitis
Authors: R. Ahola, A. Siiki, K. Vasama, M. Vornanen, J. Sand, J. Laukkarinen et al.
Notes: Centralization influences long‐term survival
Systematic review of transarterial embolization for hepatocellular adenomas. BJS 2017; 104: 823-835.
Authors: B. V. van Rosmalen, R. J. S. Coelen, M. Bieze, O. M. van Delden, J. Verheij, C. H. C. Dejong et al.
Notes: Safe alternative to surgery
Meta‐analysis of adjuvant therapy following curative surgery for periampullary adenocarcinoma. BJS 2017; 104: 814-822.
Authors: A. Acharya, S. R. Markar, M. H. Sodergren, G. Malietzis, A. Darzi, T. Athanasiou et al.
Notes: No benefit
Authors: T. Ebata, T. Mizuno, Y. Yokoyama, T. Igami, G. Sugawara, M. Nagino et al.
Notes: irresectability revisited
Survival benefit of liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma. BJS 2017; 104: 1045-1052.
Authors: H. Kim, S. W. Ahn, S. K. Hong, K. C. Yoon, H.‐S. Kim, Y. R. Choi et al.
Notes: Selected patients benefit